Target intelligence / Profile preview

Cutaneous microbiome composition

Molecular classification
Other
01

Overview

Cutaneous microbiome composition refers to the diverse and dynamic community of microorganisms—including bacteria (predominantly Actinobacteria, Firmicutes, Proteobacteria, and Bacteroidetes), fungi, viruses, archaea, and mites—that inhabit the skin. This composition varies by anatomical location, age, physiology, environmental exposure, and disease state[1][3][5][6]. The skin microbiome plays key roles in maintaining skin health by protecting against pathogens, modulating immune responses, producing nutrients, and regulating epidermal differentiation[1][3][6]. Disruptions in this community—termed dysbiosis—are linked to a range of skin diseases, including atopic dermatitis, psoriasis, and acne[3][4][2]. While the skin microbiome itself is not a molecular therapeutic target (such as a receptor or enzyme), it represents a complex ecological feature increasingly considered for interventional strategies, such as bacteriotherapy and probiotic-based treatments[4][8]. The concept of targeting the microbiome composition as a whole, rather than a single molecule, is still emerging and remains largely investigational[6][4].

Other names
skin microbiome compositionskin microbiota compositioncutaneous microbiota compositionskin microflora composition
02

Mechanism of action

Restoration or modulation of microbial balance Competitive exclusion of pathogens by commensals Induction of antimicrobial peptides and immune responses

03

Biological functions

Maintenance of skin homeostasisProtection against pathogensModulation of immune responsesRegulation of epidermal differentiationNutrient synthesis (vitamins, amino acids)
04

Disease associations

InfectionInflammationAtopic dermatitisPsoriasisAcneSeborrheic dermatitisAlopecia areataOther (as related to dysbiosis in skin disorders)
05

Safety considerations

Risk of pathogen overgrowth with microbiome disruptionUnpredictable response to live microbial therapies (bacteriotherapy)Potential allergic or inflammatory reactions to introduced strainsUnknown long-term effects of altered skin microbial ecosystems
06

Interacting drugs

Live biotherapeutic products (experimental/probiotics)

4 more in the full profile.

07

Biomarkers

Relative abundance of Staphylococcus aureus, Cutibacterium, Corynebacterium (used in research/diagnostics for cutaneous disorders)Microbial diversity indices (Shannon diversity, etc.)Presence/absence of specific commensal taxa

Beyond the preview

Go deeper on Cutaneous microbiome composition.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cutaneous microbiome composition.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call